CEBP http://www.cancermicroenvironment.tau.ac.il/welcome2009.html Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Epidemiology Biomarkers & Prevention 16, 572, March 1, 2007. doi: 10.1158/1055-9965.EPI-06-0566
© 2007 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cybulski, C.
Right arrow Articles by Lubiñski, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cybulski, C.
Right arrow Articles by Lubiñski, J.

Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27

Cezary Cybulski1, Bartlomiej Gliniewicz1, Andrzej Sikorski1, Józef Kladny1, Tomasz Huzarski1, Jacek Gronwald1, Tomasz Byrski1, Tadeusz Debniak1, Bohdan Gorski1, Anna Jakubowska1, Dominika Wokolorczyk1, Steven A. Narod2 and Jan Lubiñski1

1 Pomeranian Medical University, Szczecin, Poland and 2 Centre for Research on Women's Health, University of Toronto, Toronto, Ontario, Canada

Requests for reprints: Steven A. Narod, Centre for Research on Women's Health, University of Toronto, 790 Bay Street, Toronto, Ontario, Canada M5G IN8. Phone: 416-351-3765; Fax: 416-351-3767. E-mail: steven.narod{at}wchospital.ca

We studied the effects of p27 and CHEK2 variants on prostate and colon cancer risk in a case-control study. Modest effects on prostate cancer risk were observed for both CHEK2 missense and truncating variants. However, the excess cancer risk was restricted to the subgroup of men who were homozygous for the VV genotype in codon 109 of the p27 gene. Among men with the VV p27 genotype, the odds ratios associated with truncating and missense CHEK2 mutations were 3.1 (P < 0.0001) and 1.9 (P < 0.0001), respectively. Among men with other p27 genotypes (GG and VG), the odds ratios were 1.5 and 1.2 for truncating and missense CHEK2 mutations, respectively, and were not statistically significant. The interaction between CHEK2 and p27 was confirmed in a group of patients with colon cancer. Thus, it seems that the clinical expression of CHEK2 variant alleles on prostate and colon cancer risk may be restricted to individuals with a specific genotype (VV) of the p27 gene. Two-gene models provide numerous challenges for gene identification and cancer risk assessment. (Cancer Epidemiol Biomarkers Prev 2007;16(3):572–6)




This article has been cited by other articles:


Home page
Cancer Res.Home page
S. Zhang, C. M. Phelan, P. Zhang, F. Rousseau, P. Ghadirian, A. Robidoux, W. Foulkes, N. Hamel, D. McCready, M. Trudeau, et al.
Frequency of the CHEK2 1100delC Mutation among Women with Breast Cancer: An International Study
Cancer Res., April 1, 2008; 68(7): 2154 - 2157.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.